Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 167Neoplasms 30Neoplasm Metastasis 29Brain Neoplasms 16Breast Neoplasms, Male 15Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Stomach Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 6Colorectal Neoplasms 6Prostatic Neoplasms 5Inflammatory Breast Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Esophageal Neoplasms 4Carcinoma, Ovarian Epithelial 4Unspecified Adult Solid Tumor, Protocol Specific 3Salivary Gland Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Lung Neoplasms 3Gliosarcoma 3Glioma 3Gallbladder Neoplasms 3Ependymoma 3Carcinoma, Squamous Cell 3Triple Negative Breast Neoplasms 2Solid Tumors 2Osteitis Deformans 2

Interventions

Trastuzumab 4pyrotinib 3Vinorelbine 2pertuzumab 1copanlisib 1Lapatinib 1Docetaxel 1Carboplatin 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Positive Breast Cancer × Lapatinib × Clear all
NCT02362958 2020-07-15

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Sun Yat-sen University

Phase 2 Completed
159 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡